Metabonomics is defined as the "quantitative measurement of time-related multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification" (Nicholson et al., 1999) . More practically, metabonomics encompasses the application of nuclear magnetic resonance (NMR) spectroscopy, pattern recognition tools, and multivariate statistical methods to the evaluation of endogenous metabolites in biofluids and tissues. This technology represents a potentially powerful method for determining the systemic response to toxicity or disease.
are frequently detected include hippurate, creatine, and taurine . However, there is clear evidence that the pattern of changes noted, even with these commonly occurring metabolites, is altered in a toxicity-and tissue-specific manner, a feature that is extremely powerful with respect to the predictive utility of metabonomic data. At the same time, there is the clear potential to identify unique and/or specific endogenous metabolites that are associated with a specific type of change, enabling the identification of biomarkers of toxic changes.
One issue with metabonomic analyses concerns its overall sensitivity to environmental and physiological changes. For example, age-dependent changes in renal function in rats, especially male rats, alters the typical urinary profile observed in untreated rats (Robertson et al., 2000) . Similarly, metabonomic changes associated with the normal estrus cycle have been reported (Bollard et al., 2001) . Furthermore, any change in the general health status of the animals, most notably alterations in the resident flora within the gastrointestinal tract, can alter typical metabonomic profiles (Nicholls et al., 2003) . Finally, because NMR is a nondiscriminating tool, the profiles of compounds administered to animals to evaluate metabonomic changes can confound the interpretation of the NMR data. Importantly, some commonly used vehicles for compound administration are not compatible with metabonomics applications, most notably Labrofil and polyethylene glycol (Beckwith-Hall et al., 2002) .
Given the amount of data generated from a single NMR spectrum, data analysis is a critical component of the interpretation of metabonomic results. Principal component analysis (PCA) is a widely used tool used to identify those analytes that are most different from the control and provides for a visual characterization of the data set. However, for pattern recognition and predictive model development, additional multivariate statistical models are required. Accordingly, the successful application of metabonomic data to toxicology issues will always require the coordinated, multidisciplinary effort of toxicologists, NMR spectroscopists, statisticians and bioinformaticists.
To date, metabonomic analyses in toxicology have focused mainly on the identification of changes associated with liver or kidney toxicity. In this regard, changes detected in metabonomic patterns do not always directly correlate with histopathological changes and frequently precede those detected through clinical chemistry analyses. However, after extensive data analysis and application of pattern recognition tools, it is clear that metabonomic data can be used to accurately classify compounds as causing hepatic and/or kidney injury (Holmes et al., 2000) . More recent, broader investigations have also shown that metabonomic data can also be used to assess the development of vascular lesions and vasculitis in rats (Robertson et al., 2001; Slim et al., 2002) . Metabonomic evaluations have also been used to identify potential biomarkers of toxicity. One such example is the detection of phenylacetylglycine (PAG) as a potential useful biomarker for compound-induced phospholipidosis (Espina et al., 2001) . As with any biomarker, careful validation is required to assess the overall utility of the biomarker (across species, sensitivity, and specificity) and efforts continue in this regard. However, a biomarker need not be a single metabolite. For example, the combination of changes in the urinary levels of four metabolites (trimethylamine-Noxide, N ,N -dimethylglycine, dimethylamine and succinate) has been shown to accurately predict renal papillary necrosis (Holmes et al., 1995) . Prior to the application of metabonomics, the diagnosis of both phospholipidosis and renal papillary necrosis required histopathological evaluation. Accordingly, the ability to assess these toxicities by metabonomic analysis of urine represents an important scientific advancement.
Many metabonomic studies conducted to date have focused on assessing the patterns of change associated with toxicity and reporting the kinds metabolites that have been altered by chemical treatment or physiological alteration. These reports are extremely useful for establishing databases that can be used for predicting toxic liabilities. However, efforts to use metabonomics to identify mechanisms of toxicity are also important. For example, recent work from MortishireSmith et al. (2004) provided evidence of altered fatty acid metabolism as a mechanism of hepatotoxicity and show the potential for metabonomics to address mechanistically based hypotheses.
As use of metabonomics advances, it is important to recognize that there are several challenges facing scientists using this tool that must be addressed in order to make it more mainstream and more relevant to hazard identification and human risk assessment. First, advancing the use of metabonomics to identify mechanisms of toxicity is essential, and such efforts should help to increase the overall usefulness, validity and relevance of toxicity prediction and biomarker development. Second, the application of metabonomics to biomarker identification from animal studies that can be translated to clinical use is an important challenge. To this end, rats have been the major animal model used in most metabonomic evaluations, but extension to other preclinical species, including nonhuman primates, is important. Ultimately, clinical evaluation of the technology is an important challenge and goal, and early work suggests that this will be feasible (Lenz et al., 2003) . Finally, although metabonomic data can be used independently to evaluate disease state or chemically induced insult, the integration of metabonomic data with other tools, particularly toxicogenomics and proteomics, is critical and may also help to validate results obtained from these other approaches.
